Role of mucosal adjuvants in mucosal immunization

Current Opinion in Gastroenterology

Volumn 14, Issue 6, 1998, Pages 483-487

  Oliver, Alfred R ^a   Elson, Charles O ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; ENTEROTOXIN; ESCHERICHIA COLI ENTEROTOXIN; MEMBRANE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; BACTERIAL MEMBRANE; BACTERIAL TRANSLOCATION; ENZYME ACTIVITY; IMMUNE RESPONSE; IMMUNIZATION; INTESTINE MUCOSA; NONHUMAN; SHORT SURVEY; T LYMPHOCYTE; TARGET CELL;

EID: 0032452534     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199811010-00011     Document Type: Short Survey

References (43)

1. Backstrom M, Shahabi V, Johansson S, Teneberg S, Kjellberg A, Miller-Podraza H, Holmgren J, Lebens M: Structural basis for differential receptor binding of cholera and Escherichia coli heat-labile toxins: influence of heterologous amino acid substitutions in the cholera B-subunit. Mol Microbiol 1997, 24:489-497.
2. Kubota M, Miller CJ, Imaoka K, Kawabata S, Fujihashi K, McGhee JR, Kiyono H: Oral immunization with simian immunodeficiency virus p55gag and cholera toxin elicits both mucosal IgA and systemic IgG immune responses in nonhuman primates. J Immunol 1997, 158:5321-5329. Cholera toxin has adjuvant activity in nonhuman primates.
3. 1 responses against some antigens.
4. 1 responses against some antigens.
5. Takahashi I, Marinaro M, Kiyono H, Jackson RJ, Nakagawa I, Fujihashi K, Hamada S, Clements JD, Bost KL, McGhee JR: Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J Infect Dis 1996, 173:627-635.
6. Bergquist C, Johansson EL, Lagergard T, Holmgren J, Rudin A: Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect Immun 1997, 65:2676-2684.
7. Blanchard TG, Lycke N, Czinn SJ, Nedrud JG: Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter felis. Immunology 1998, 94:22-27.
8. Tochikubo K, Isaka M, Yasuda Y, Kozuka S, Matano K, Miura Y, Taniguchi T: Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin. Vaccine 1997, 16:150-155.
9. de Geus B, Dol-Bosman M, Scholten JW, Stok W, Bianchi A: A comparison of natural and recombinant cholera toxin B subunit as stimulatory factors in intranasal immunization. Vaccine 1997, 15:1110-1113.
10. Wu HY, Russell MW: Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant. Vaccine 1998, 16:286-292.
11. 1.
12. Elson CO, Holland SP, Dertzbaugh MT, Cuff CF, Anderson AO: Morphologic and functional alterations of mucosal T cells by cholera toxin and its B subunit. J Immunol 1995, 154:1032-1040.
13. Nashar TO, Webb HM, Eaglestone S, Williams NA, Hirst TR: Potent immunogenicity of the B subunits of Escherichia coli heat-labile enterotoxin: receptor binding is essential and induces differential modulation of lymphocyte subsets. Proc Natl Acad Sci U S A 1996, 93:226-230.
14. Nashar TO, Williams NA, Hirst TR: Cross-linking of cell surface ganglioside GM1 induces the selective apoptosis of mature CD8+ T lymphocytes. Int Immunol 1996, 8:731-736.
15. Truitt RL, Hanke C, Radke J, Mueller R, Barbieri JT: Glycosphingolipids as novel targets for T-cell suppression by the B subunit of recombinant heat-labile enterotoxin. Infect Immun 1998, 66:1299-1308. This article shows that LTB binds to and induces apoptosis in CD8+ T cells.
16. 1 is essential for the immunogenicity and adjuvant activity of orally administered LT.
17. Nashar TO, Hirst TR, Williams NA: Modulation of B cell activation by the B subunit of Escherichia coli enterotoxin: receptor interaction up-regulates MHC class II. B7, CD40, CD25 and ICAM-1 Immunology 1997, 91:572-578. This article shows that LTB enhances the expression of several important activation and costimulatory molecules on B cells.
18. Yamamoto S, Kiyono H, Yamamoto M, Imaoka K, Fujihashi K, Van Ginkel FW, Noda M, Takeda Y, McGhee JR: A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc Natl Acad Sci U S A 1997, 94:5267-5272. Cholera toxin with mutations in the enzymatic site had adjuvant activity when given intranasally in mice.
19. Douce G, Fontana M, Pizza M, Rappuoli R, Dougan G: Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect Immun 1997, 65:2821-2828.
20. Giuliani MM, Del Giudice G, Giannelli V, Dougan G, Douce G, Rappuoli R: Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J Exp Med 1998, 187:1123-1132. Trace levels of enzymatic activity are sufficient for the adjuvant activity of a genetically engineered LT mutant.
21. Chong C, Friberg M, Clements JD: LT (R192G), a non-toxic mutant of the heat-labile enterotoxin of Eschericia coli, elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp. Vaccine 1998, 16:732-740.
22. Marchetti M, Rossi M, Giannelli V, Giuliani MM, Pizza M, Censini S, Covacci A, Massari P, Pagliaccia C, Manetti R: Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. Vaccine 1998, 16:33-37.
23. 1 subunit of CT, genetically fused to immunoglobulin-binding domains, has adjuvant activity, suggesting a role for B cells in the adjuvant activity of CT.
24. Cong Y, Weaver CT, Elson CO: The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective up-regulation of B7.2 expression. J Immunol 1997, 159:5301-5308. Cholera toxin and CTB increase expression of B7.2 on antigen-presenting cells, and antibodies to B7.2 reduce adjuvanticity in vivo.
25. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA, Weiner HL, Nabavi N, Glimcher LH: B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995, 80:707-718.
26. Grdic D, Hornquist E, Kjerrulf M, Lycke NY: Lack of local suppression in orally tolerant CD8-deficient mice reveals a critical regulatory role of CD8+ T cells in the normal gut mucosa. J Immunol 1998, 160:754-762. Oral antigen administration induces strong intestinal IgA responses in CD8-deficient but not wild-type mice, suggesting that CD8+ T cells are important regulatory cells in the gut.
27. Tomasi M, Dertzbaugh MT, Hearn T, Hunter RL, Elson CO: Strong mucosal adjuvanticity of cholera toxin within lipid particles of a new multiple emulsion delivery system for oral immunization. Eur J Immunol 1997, 27:2720-2725. Orally administered CT has adjuvant activity when delivered within a matrix that prevents contact with the gut epithelium and delivers antigens to Peyer's patches.
28. Kjerrulf M, Grdic D, Ekman L, Schon K, Vajdy M, Lycke N, Y.: Interferon-γ receptor-deficient mice exhibit impaired gut mucosal immune responses but intact oral tolerance. Immunology 1997, 92:60-68. T is immunogenic but has no adjuvant activity in orally immunized IFN-γ receptor deficient mice.
29. 2 subunit of CT induce immune responses to the linked antigen.
30. Hajishengallis G, Hollingshead SK, Koga T, Russell MW: Mucosal immunization with a bacterial protein antigen genetically coupled to cholera toxin A2/B subunits. J Immunol 1995, 154:4322-4332.
31. Toida N, Hajishengallis G, Wu HY, Russell MW: Oral immunization with the saliva-binding region of Streptococcus mutans AgI/II genetically coupled to the cholera toxin B subunit elicits T-helper-cell responses in gut-associated lymphoid tissues. Infect Immun 1997, 65:909-915.
32. Sun JB, Rask C, Olsson T, Holmgren J, Czerkinsky C: Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc Natl Acad Sci U S A 1996, 93:7196-7201.
33. Bergerot I, Ploix C, Petersen J, Moulin V, Rask C, Fabien N, Lindblad M, Mayer A, Czerkinsky C, Holmgren J: A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci U S A 1997, 94:4610-4614. Constructs in which insulin is linked to CTB treat experimental autoimmune diabetes by enhancing oral tolerance.
34. Sasaki S, Hamajima K, Fukushima J, Ihata A, Ishii N, Gorai I, Hirahara F, Mohri H, Okuda K: Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type 1 with a DNA-monophosphoryl lipid A adjuvant vaccine. Infect Immun 1998, 66:823-826.
35. VanCott TC, Kaminski RW, Mascola JR, Kalyanaraman VS, Wassef NM, Alving CR, Ulrich JT, Lowell GH, Birx DL: HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp 160. J Immunol 1998, 160:2000-2012.
36. 1 responses to the vaccine.
37. Smith RE, Donachie AM, Mclaren FA, and Mowat AM: Preservation of mucosal and systemic adjuvant properties of ISCOMS in the absence of functional interleukin-4 or interferon-γ. Immunology 1998, 93:556-562. In contrast to previous findings with CT, immune-stimulating complexes have adjuvant activity in IL-4 or IFN-γ receptor deficient mice.
38. Lomotan EA, Brown KA, Speaker TJ, Offita PA: Aqueous-based microcapsules are detected primarily in gut-associated dendritic cells after oral inoculation of mice. Vaccine 1997, 15:1959-1962. Peyer's patch dendritic cells may be important targets for the adjuvant activity of orally administered microcapsules.
39. Eyles JE, Sharp GJE, Williamson ED, Spiers ID, Alpar HO: Intranasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse. Vaccine 1998, 16:698-707.
40. Higaki M, Takase T, Igarashi R, Suzuki Y, Aizawa C, Mizushima Y: Enhancement of immune response to intranasal influenza HA vaccine by microparticle resin. Vaccine 1998, 16:741-745.
41. Ugozzoli M, O'Hagan DT, Ott GS: Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses. Immunology 1998, 93:563-571.
42. Godefroy OP, Mielcarek N, Ivanoff N, Remoue F, Schacht AM, Phillips N, Locht C, Capron A, Riveau G: Bordetella pertussis filamentous hemagglutinin enhances the immunogenicity of liposome-delivered antigen administered intranasally. Infect Immun 1998, 66:1764-1767.
43. Erdile LF, Guy B: OspA lipoprotein of Borrelia burgdorferi is a mucosal immunogen and adjuvant. Vaccine 1997, 15:988-996.